http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
이문호,김정수 한국인터넷방송통신학회 2021 한국인터넷방송통신학회 논문지 Vol.21 No.2
1893년 불란서 Hadamard가 발표한 직교 Hadamard 행렬에 대해 이문호교수는 1989년에 Center Weight Hadamard로 새롭게 정의하여 발표했고 1998년에는 Jacket 행렬을 발견했다. Jacket 행렬은 Hadamard 행렬을 일반 화한 것이다. 본 논문에서는 Symmetric Jacket 행렬을 구해 중요한 속성과 패턴을 분석하고 Jacket 행렬의 행렬식과 Eigenvalue을 얻는 방법을 제시하며 Eigen decomposition를 사용하여 이를 증명했다. 이러한 계산은 신호 처리 및 직교 코드 설계에 유용하다. 행렬의 체계를 분석하기 위해 DFT, DCT, Hadamard, Jacket 행렬로 비교해 본다. Galois Field의 대칭 행렬에서 Jacket 행렬의 element-wise inverse 관계를 수학적으로 증명하고 직교 성질 AB=I 관계를 유도했다. About the orthogonal Hadamard matrix announced by Hadamard in France in 1893, Professor Moon Ho Lee newly defined it as Center Weight Hadamard in 1989 and announced it, and discovered the Jacket matrix in 1998. The Jacket matrix is a generalization of the Hadamard matrix. In this paper, we propose a method of obtaining the Symmetric Jacket matrix, analyzing important properties and patterns, and obtaining the Jacket matrix's determinant and Eigenvalue, and proved it using Eigen decomposition. These calculations are useful for signal processing and orthogonal code design. To analyze the matrix system, compare it with DFT, DCT, Hadamard, and Jacket matrix. In the symmetric matrix of Galois Field, the element-wise inverse relationship of the Jacket matrix was mathematically proved and the orthogonal property AB=I relationship was derived.
착색용액과 Monolithic Zirconia를 이용한 심미적인 부위의 보철 치료
이문호,김준성,박은철,김희중 大韓齒科補綴學會 2022 대한치과보철학회지 Vol.60 No.3
Various materials and restorative options have been introduced recently with growing interest in esthetic dental treatment in modern society. Zirconia is especially known for its biocompatibility as well as remarkable toughness and resistance to wear, but it is limited in its use for esthetically focused treatment in anterior region for its white opacity. Lately the development of different kinds of zirconium blocks, such as colored block, clear block, and multi-layered block, allowed more extensive use of zirconia as a treatment option. This report describes a case, in which a prosthetic crown maxillary anterior region was stained with a combination of various coloring liquids before sintering to reproduce natural-looking color scheme in final restoration. The case was reported as the utilization of coloring liquid on monolithic zirconia crown could achieve esthetically satisfying prosthesis for both dentist and patient. 최근 현대인들의 심미적인 치과 치료에 대한 관심이 증가하고 있고, 이와 관련된 다양한 재료와 수복물이 소개되고 있다. 특히 지르코니아는 우수한 강도와 내마모성을 지니며 생체친화성이 있다. 이러한 장점에도 불구하고, 지르코니아의 불투명한 백색으로 인해 전치부 수복치료시 심미적인 한계점이 있다. 최근 색조를 부여한 지르코니아 블록과 투명성이 높은 지르코니아 블록 및 다층 지르코니아 블록 등 다양한 지르코니아 블록이 개발되면서 단일 구조 지르코니아의 활용 범위가 확대되고 있다. 본 증례는 상악 전치부 보철물을 제작을 위해 단색의 Monolithic Zirconia를 이용하여 소결 전에 착색 용액을 도포하여 최종 수복물의 색조를 자연스럽게 재현하였다. 심미 보철 수복 치료시 착색용액을 이용한 지르코니아 사용을 통해 환자와 술자 모두 만족하는 심미적 보철물을 제작하였기에 이를 보고하는 바이다.
Graves 병에서 배양된 쥐 갑상선 세포 (FRTL-5)를 이용한 갑상선 성장자극항체와 갑상선 아데닐사이클라제 자극항체의 동시측정
이문호,조보연,문대혁,고창순,이기업,송영기,이명혜 대한내분비학회 1991 Endocrinology and metabolism Vol.6 No.1
The relationship between thyroid growth stimulating antibody (TGSab) and thyroid adenylate cyclase stimulating antibody (Tsab) in patients with Graves' disease is of great controversy. To investigate the nature of TGSab, we measured TGSab and Tsab simultaneously using FRTL-5 cells. TGSab was measured by [3H]-thymidine incorporation, and Tsab by cAMP increase. Forty out of 46 (87%) untreated Graves' patients had detectable TGSab, and 42 (91.3%) had Tsab. TGSab was detected in 18 out of 34 (52.9%) Graves' patients under drug treatment and 4 out of 18 (22.2%) patients with Graves' disease in remission. Of 22 patients with goitrous Hashimoto's thyroiditis 8 (36.4%) had TGSab and none of 23 patients with primary myxedema had TGSab. Of 19 patients with nodular goiter, two (10.6%) had TGSab. Presence of TGSab activity was significantly associated with untreated Graves' disease. In patients with Graves' disease, TGSab activity was significantly correlated with estimated in vivo goiter size (rs=0.68, p<0.001). A significantly positive correlation was found between TGSab and Tsab (r=0.63, p<0.001), and also between TGSab and TBII(r=0.48, p<0.01) in patients with untreated Graves' disease. IgG from a patient with primary myxedema, previously shown to inhibit TSH-stimulated thyroid adenylate cyclase, inhibited both TSH and Graves' IgG stimulated [3H]-thymidine incorporation. Adenosine, which inhibits thyroid adenylate cyclase activation, also inhibited both TSH and Graves'IgG stimulated [3H]-thymidine incorporation into FRTL-5 cells. In conclusion, TGSab might be a thyrotropin receptor antibody which exerts its action through cAMP increase, in other word, TGSab might be almost identical to Tsab in Graves' disease, causing goiter and hyperthyroidism(J Kor Soc Endocrinol 6:17 24, 1991).